News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Ad hoc: Epigenomics issues new shares to BioChain – Investment follows agreement on broad strategic collaboration in China

PDF 39 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that BioChain and certain of its shareholders will invest US$ 1.3 million (EUR 0.94 million) into the Company by subscribing 217,935 newly issued shares. This investment follows the signing of an agreement regarding a broad strategic collaboration of both companies announced today. Executive […]

Read more

Ad hoc: Epigenomics signs joint commercialization agreement for Epi proColon® in North America with Polymedco

PDF 37 KB   Berlin, Germany– Epigenomics AG (ISIN: DE000A1K0516) announces that it has entered into a joint commercialization agreement with Polymedco Inc. Both companies will jointly commercialize Epi proColon®, Epigenomics’ blood-based test for colorectal cancer (CRC) screening, in North America. Under the terms of the agreement, Polymedco will deploy its CRC dedicated sales force […]

Read more

Epigenomics AG issues EUR 500,000 in convertible bonds to YA Global Master SPV Ltd.

PDF 84 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516, OTC: EPGNY) announces that upon registration of the conditional capital of the Company today successfully completed the issuance of convertible bonds with a nominal amount of EUR 500,000. These convertible bonds constitute the first tranche of a total issuance of up to EUR 5m […]

Read more

Ad hoc: Epigenomics AG secures financing of up to EUR 5m

PDF 80 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that it has entered into an agreement with YA Global Master SPV Ltd. through which it secured a convertible bond financing for up to EUR 5m. Under the terms of the agreement, YA Global Master SPV Ltd., over a period of up to […]

Read more

Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

PDF 76 KB   Not for distribution in the United States Berlin, Germany – The Executive Board of Epigenomics AG (ISIN: E000A1K0516) notifies that during the preparation of the annual financial statements pursuant to German GAAP (HGB) accounting, according to its best judgment a cumulative loss of more than half of the nominal share capital […]

Read more

Ad hoc: Epigenomics AG Reports Non-Inferiority of Blood-based Epi proColon® against Fecal Immunochemical Testing in Detection of Colorectal Cancer in a Head-to-Head Comparative Study

PDF 85 KB   Berlin, Germany, December 04, 2012 – Epigenomics AG (ISIN: DE000A1K0516) announces top-line results from a head-to-head comparative study between its blood-based colorectal cancer (CRC) detection test Epi proColon® and fecal immunochemical testing (FIT) to demonstrate the non-inferiority of Epi proColon® in detection of CRC. In the reported trial, Epi proColon® detected […]

Read more